NAME: 	pENTR223 
RESISTANT MARKER:	Spectinomycin resistant; 100 ��g/ml
SOURCE: 	Dana Farber Cancer Institute/Vidal Lab
V_TYPE: 	Gateway entry vector
SEQUENCING PRIMERS: 	M13(-21), T7
POLYLINKER SEQUENCE: 
CAACAGATAAAACGAAAGGCCCAGTCTTCCGACTGAGCCTTTCGTTTTAT
TTGATGCCTGGCAGTTCCCTACTCTCGCGTTAACGCTAGCATGGATGTTT
TCCCAGTCACGACGTTGTAAAACGACGGCCAGTCTTAAGCTCGGGCCCCA
AATAATGATTTTATTTTGACTGATAGTGACCTGTTCGTTGCAACAAATTG
ATGAGCAATGCTTTTTTATAATGCCAACTTTGTACAAAAAAGTTG-link
er-ORF-linker-CCAACTTTCTTGTACAAAGTTGGCATTATAAGAAAG
CATTGCTTATCAATTTGTTGCAACGAACAGGTCACTATCAGTCAAAATAA
AATCATTATTTGCCATCCAGCTGATATCCCCTATAGTGAGTCGTATTACA
TGGTCATAGCTGTTTCCTGGCAGCTCTGGCCCGTGTCTCAAAATCTCTGA
TGTTACATTGCACAAGATAAAAATATATCATCATGCCTCCTCTAGACCAG
CCAGGACAGAAATGCCTCGACTTCGCTGC

Note the specific antibiotic to be used with this vector.
Confirm sequencing primer sequences match vector before sequencing.

All ORF clones are provided in Entry Vectors for the Invitrogen GatewayR cloning system. Invitrogen offers a whole range of Destination Vectors for a wide range of applications. Refer to the homepage of Invitrogen for further information on the GatewayR cloning system and related Invitrogen products at:
http://www.invitrogen.com/content.cfm?pageid=4072 
For further information on the ORFeome Collaboration, visit their homepage at http://www.orfeomecollaboration.org/html/index.shtml.
For further technical information visit our homepage at: http://www.dnaform.jp or contact us under: techinfo@dnaform.jp.